Genentech Pauses Global Belvarafenib Melanoma Phase 1b Trial, Returns Rights to Hanmi Pharmaceutical
Roche's Restructuring and Return of Global Rights
Roche's subsidiary, Genentech, decided to return the global development rights for Belvarafenib to Hanmi Pharmaceutical as part of a pipeline optimization process in early 2024. This decision is more a result of Roche's group-wide policy to restructure its new drug pipeline by 20%, rather than concerns about the drug's efficacy. Genentech has stopped enrolling new patients in the ongoing Phase 1b clinical trial (NCT04835805) for advanced melanoma, but will continue to administer the drug and monitor existing patients until the planned completion date of June 2027. The original agreement in 2016 involved a total of $910 million, and the return of this project at a stage close to global commercialization puts the R&D risk management capabilities of the domestic bio industry to the test.
Overcoming Resistance with a Triple Combination Therapy
The global Phase 1b clinical trial (NCT04835805) is evaluating Belvarafenib alone, as well as in combination with Cobimetinib (brand name 'Cotellic'), a MEK inhibitor, and Nivolumab (brand name 'Opdivo'), a PD-1 immune checkpoint inhibitor, in patients with advanced melanoma who have NRAS gene mutations. NRAS-mutated melanoma is difficult to treat because it does not respond to existing BRAF-targeted anticancer drugs and is highly resistant to first-line immune checkpoint inhibitors. Researchers designed a multi-faceted mechanism to simultaneously block the MAPK signaling pathway, which promotes cancer cell growth, at both the upstream RAF protein (Belvarafenib) and downstream MEK protein (Cobimetinib) levels, while also activating the immune system (Nivolumab) to block the cancer cells' bypass resistance pathways. Although the global trial led by Genentech has been scaled down, the accumulated data will be an important academic asset to demonstrate the validity of next-generation combination therapies.
Hanmi Pharmaceutical's Independent Route to Phase 2
Despite Genentech's decision to discontinue development, Hanmi Pharmaceutical, the original developer, believes in the clinical value of Belvarafenib and is pursuing an independent domestic development strategy. Hanmi Pharmaceutical retained full development rights in Korea, and in early 2026, it received independent approval from the Ministry of Food and Drug Safety (MFDS) to initiate a Phase 2 trial of Belvarafenib in combination with Cobimetinib, and has begun dosing patients. This proactive move by Hanmi Pharmaceutical, in a situation where a global big pharma's discontinuation could be seen as a death sentence for the drug, reflects strong confidence in the drug's efficacy data. Depending on the results of the domestic Phase 2 trial, it may be possible to pursue re-licensing to other global partners or to achieve commercial success through early launch in the domestic market.
Fierce Global Competition for Niche Market
The global melanoma treatment market is estimated at $5.8 billion to $7.7 billion in 2026 and is projected to reach $19 billion by 2035, making it a high-value market. Of this, the NRAS gene mutation segment, which accounts for approximately 15% to 20% of all patients, currently has no approved targeted therapies, resulting in a significant unmet medical need. While Belvarafenib is trying to provide a solution, competitors such as Revolution Medicines' active RAS (ON) multi-inhibitor, Daraxonrasib (RMC-6236), and Novartis' Naporafenib are accelerating their clinical development, posing a threat. In order for Hanmi Pharmaceutical to secure the 'First-in-class' title, it must quickly obtain domestic clinical data and demonstrate superior clinical efficacy compared to its competitors.
Global big pharma Genentech's decision to return the rights to Belvarafenib, a drug with a $910 million agreement, and to halt the Phase 1b trial, is a short-term negative for large-cap bio investors, reminding them of the risks and uncertainties of new drug R&D portfolios. However, with Hanmi Pharmaceutical, the original developer, quickly entering a Phase 2 trial in Korea based on its domestic rights, there is still potential for independent development success and overseas re-licensing in the medium to long term. The global melanoma treatment market is expected to reach up to $7.7 billion in 2026, with NRAS mutations accounting for 15% to 20% of the market, and the lack of dedicated targeted therapies is a strong factor in preserving the drug's value. With global competitors such as Revolution Medicines' RMC-6236 accelerating the development of RAS(ON) inhibitors, Hanmi Pharmaceutical's clinical speed and demonstration of safety will be the key to its corporate value and commercial recovery. Ultimately, the accumulated data from the Phase 1b trial and the objective data from the domestic Phase 2 trial will be a litmus test for evaluating the domestic bio industry's ability to independently commercialize its technology.
Source: ClinicalTrials.gov (api_ct)